BMY

Bristol-Myers Squibb Co

65.31

Jul 31 • 3:59 PM ET +0.45 (0.69%)

65.40

Aftermarket • 7:58 PM ET +0.09 (0.13%)

Healthcare Drug Manufacturers - General USA Large NYSE

Jul 30, 5:46 PMBristol Myers Squibb beats Q2 2026 estimates, raises 2024 and 2026 guidance, delays key Milvexian and Cobenfy pivotal readouts to early 2027

Peers: PFE MRK ABBV JNJ LLY AZN NVS AMGN GILD GSK

| Held by: VTI SCHD VOO IVV SPY VTV XLV JEPI VYM COWZ

Scroll to Statements

Index	S&P 500
Market Cap	133.41B
Enterprise Value	167.40B
Income	9.28B
Sales	49.20B
Book/sh	10.92
Cash/sh	5.42
Dividend Est.	2.34 (3.58%)
Dividend TTM	2.51 (3.84%)
Dividend Ex-Date	Jul 02, 2026
Dividend Gr. 3/5Y	4.37% 6.24%
Payout	71.98%
Employees	32500
IPO	Jul 05, 1929

P/E	14.39
Forward P/E	10.14
PEG	-
P/S	2.71
P/B	5.98
P/C	12.05
P/FCF	11.66
EV/EBITDA	8.72
EV/Sales	3.40
Quick Ratio	1.38
Current Ratio	1.53
Debt/Eq	2.02
LT Debt/Eq	1.96
Option/Short	Yes / Yes

EPS (ttm)	4.54
EPS next Y	6.44
EPS next Q	1.70
EPS this Y	9.65%
EPS next Y	-4.47%
EPS next 5Y	-3.29%
EPS past 3/5Y	5.47% -
Sales past 3/5Y	1.45% 2.54%
EPS Y/Y TTM	83.17%
Sales Y/Y TTM	3.13%
EPS Q/Q	49.96%
Sales Q/Q	6.22%
Earnings	Jul 30 BMO
EPS/Sales Surpr.	27.73% 10.51%

Insider Own	0.32%
Insider Trans	-0.46%
Inst Own	82.65%
Inst Trans	0.33%
ROA	10.18%
ROE	46.70%
ROIC	14.03%
Gross Margin	66.64%
Oper. Margin	32.35%
Profit Margin	18.87%
SMA20	8.05%
SMA50	12.37%
SMA200	17.53%
Trades

Shs Outstand	2.04B
Shs Float	2.04B
Short Float	2.21%
Short Ratio	3.78
Short Interest	44.94M
52W High	65.56 -0.38%
52W Low	42.52 53.60%
Volatility	2.95% 2.65%
ATR (14)	1.68
RSI (14)	71.00
Beta	0.22
Rel Volume	1.23
Avg Volume	11.87M
Volume	14,580,256

Perf Week	5.19%
Perf Month	15.72%
Perf Quarter	7.79%
Perf Half Y	20.32%
Perf YTD	21.08%
Perf Year	50.80%
Perf 3Y	5.02%
Perf 5Y	-3.77%
Perf 10Y	-12.70%
Recom	2.45
Target Price	64.87
Prev Close	64.86
Price	65.31
Change	0.69%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-25-26	Initiated	RBC Capital Mkts	Sector Perform	$60
Feb-20-26	Initiated	Barclays	Overweight	$75
Jan-07-26	Upgrade	UBS	Neutral → Buy	$65
Dec-15-25	Upgrade	BofA Securities	Neutral → Buy	$61
Dec-12-25	Upgrade	Guggenheim	Neutral → Buy	$62
Nov-13-25	Initiated	Scotiabank	Sector Perform	$45
Aug-05-25	Downgrade	Daiwa Securities	Outperform → Neutral	$42
Apr-22-25	Initiated	Piper Sandler	Overweight
Apr-22-25	Initiated	Cantor Fitzgerald	Neutral	$55
Dec-16-24	Upgrade	Jefferies	Hold → Buy	$70
Dec-10-24	Resumed	BofA Securities	Neutral	$63
Nov-15-24	Initiated	Wolfe Research	Peer Perform
Nov-13-24	Upgrade	Daiwa Securities	Neutral → Outperform
Nov-12-24	Upgrade	Leerink Partners	Market Perform → Outperform	$73
Oct-25-24	Downgrade	Citigroup	Buy → Neutral	$75 → $55
Oct-17-24	Initiated	Bernstein	Mkt Perform	$56
Jul-29-24	Downgrade	Barclays	Overweight → Equal Weight	$41
Mar-11-24	Downgrade	Societe Generale	Buy → Hold
Feb-06-24	Downgrade	Redburn Atlantic	Buy → Neutral	$77 → $54
Jan-03-24	Downgrade	BofA Securities	Buy → Neutral	$68 → $60

Show Previous Ratings

Jul-31-26 01:48PM	Activist Investors Shift Back to Basics: ICR Global Head of Governance Gabriel Hasson, Live at NYSE (CorpGov.com)
Jul-30-26 11:18PM	Bristol-Myers Squibb Company Q2 2026 Earnings Call Summary (Moby)
05:06PM	Bristol-Myers Squibb Co (BMY) (Q2 2026) Earnings Call Highlights: Growth Portfolio Surges 14%, ... (GuruFocus.com)
09:50AM	Bristol Myers Squibb Lifts Full-Year Guidance After Strong Second-Quarter Earnings Beat (InvestorsHub)
08:17AM	Bristol Myers Squibb raises 2026 forecast after Q2 earnings beat (Quartz)
07:43AM	Loading…
07:43AM	Bristol-Myers Squibb raises annual outlook as Q2 tops estimates; shares up (Investing.com)
07:08AM	Bristol Myers Lifts Outlook as Profit, Revenue Rise (The Wall Street Journal)
07:06AM	Bristol Myers: Q2 Earnings Snapshot (Associated Press)
06:59AM	Bristol Myers Squibb Reports Second Quarter Financial Results for 2026 (Business Wire)
06:59AM	Bristol Myers Raises Earnings Guidance as Newer Drugs Drive Big Quarterly Beat (Barrons.com)
05:11AM	Apple and Amazon in focus on busy day of company earnings (MarketWatch)
Jul-29-26 02:11PM	The Real Price of AbbVie Stock Is Cheaper Than You Think (Trefis)
01:22PM	MapLight CEO on what investors missed in the biotechs schizophrenia data (BioPharma Dive)
05:49AM	BMS and Gilead rule in the CAR-T space. Off-the-shelf developers arent trying to change that. (Pharma Voice)
Jul-28-26 03:31PM	Replimune Is Locked in a Standoff With Regulators. Here Is What It Means for the Stock. (Barrons.com)
01:02PM	Loading…
01:02PM	Replimune shares fall after FDA reviewers raise doubts over RP1 melanoma drug efficacy (Proactive)
Jul-27-26 03:54PM	The Engine Behind ABBV Stock Has Real Parts (Trefis)
Jul-21-26 02:31PM	AbbVie Stock Zigs When The Market Zags (Trefis)
07:12AM	Bristol Myers, NVIDIA join forces to build life sciences most powerful AI factory (Pharmaceutical Technology)
Jul-20-26 04:12PM	Bristol Myers Expands NVIDIA Partnership to Build Top Life Sciences AI Supercomputer (GuruFocus.com)
02:40PM	Bristol Myers Squibb expands NVIDIA AI supercomputer for drug discovery (Quartz)
08:37AM	Bristol Myers Squibb expands Nvidia AI infrastructure for drug discovery (InvestorsHub)
08:17AM	Merck's Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over. (Barrons.com)
07:01AM	Bristol Myers buys Nvidia's latest AI computing system for drug research (Reuters)
06:59AM	Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA (Business Wire)
04:54AM	Bristol Myers to build powerful AI factory; Samsung Biologics bids for peptide maker (BioPharma Dive)
02:00AM	What Comes After Merck's Keytruda? The Race for the Next Standard Cancer Treatment. (Barrons.com)
Jul-17-26 05:51PM	The Real Question Buried Inside Merck Stock's Premium Price (Trefis)
Jul-16-26 08:44AM	Why Is The Market Punishing JNJ Stock? (Trefis)
Jul-15-26 06:00AM	Eli Lilly-Backed Novel Cancer Therapy Firm Raises $315 Million (Bloomberg)
01:37PM	Loading…
Jul-13-26 01:37PM	Own Regeneron For Biotech Growth? Incyte Is Making Its Case. (Trefis)
07:46AM	Agenus surges on study pivot; Apnimed lines up an IPO (BioPharma Dive)
06:59AM	U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma (Business Wire)
Jul-09-26 10:58AM	Make Your AMGN Shares Pay You 8.7% While You Hold Them (Trefis)
09:13AM	ABBV Leads Its Peer Group. You Pay For That (Trefis)
12:38AM	SLS Stock Snaps 2-Day Slide: Sellas SLS009 AML Trial Spotlights Big Pharma Drug Combo From ABBV, RHHBY And BMY (Stocktwits)
Jul-07-26 03:33PM	2 Healthcare Stocks to Buy for Their Dividends-and Why Pfizer Isn't One of Them (Barrons.com)
Jul-02-26 06:19AM	Roche KRAS drug succeeds in head-to-head lung cancer study (BioPharma Dive)
Jun-30-26 04:10PM	US House committee opens investigation into Merck, AbbVie China drug trials (Reuters)
12:19PM	Merck, AbbVie probed by US lawmakers over China clinical trials: report (Proactive)
06:22AM	Beeline ups its Series A round for immune drug work (BioPharma Dive)
05:35AM	Genmab Shares Climb After Lymphoma Therapy Hits Goal in Trial (The Wall Street Journal)
Jun-29-26 02:33PM	AbbVie Stock Rockets 17% With 5-Day Winning Streak (Trefis)
Jun-26-26 12:03PM	AbbVie Stock's Growth Story Has One Question Mark (Trefis)
Jun-25-26 12:26AM	Revisiting Stock Picks Intel, Progressive, Bristol Myers Squibb (Barrons.com)
Jun-24-26 05:00PM	A $30 Billion Cancer Breakthrough Is Under Threat From Global Conflicts (Bloomberg)
03:32PM	The Number That Could Test AbbVie Stock (Trefis)
Jun-23-26 03:57PM	The $50B Plan Merck Stock Was Broadcasting (Trefis)
08:20AM	Should You Buy Or Sell AbbVie Stock At $230? (Trefis)
06:21AM	How Kardigan spun deal leftovers into a $400M IPO (BioPharma Dive)
Jun-22-26 10:46AM	Merck Stocks New Drugs Were Already Answering The Big Question (Trefis)
Jun-19-26 05:13AM	ASCO26: RLTs bring the buzz, but commercial and tolerability qualms remain (Pharmaceutical Technology)
Jun-18-26 08:56PM	How One Partnership Profit Line Reframes The Regeneron Pharmaceuticals Stock Story (Trefis)
04:57PM	What If Amgen Stock's Patent Worries Are Hiding Its Real Growth Engine? (Trefis)
02:03PM	Kardigan shares soar after Nasdaq debut (Investing.com)
06:59AM	Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026 (Business Wire)
Jun-17-26 04:16PM	Bristol Myers Squibb Announces Dividend (Business Wire)
06:32AM	EHA26: BMS touts positive multiple myeloma data for two pipeline candidates (Clinical Trials Arena)
Jun-16-26 04:06PM	Edgewise Bounds Between Double-Digit Losses And Gain - What's Going On? (Investor's Business Daily)
Jun-11-26 04:15PM	Takeda Designed A Psoriasis Pill Using AI. It Just Walloped Bristol's Sotyktu In A Head-To-Head Test. (Investor's Business Daily)
03:00AM	Takedas $4B TYK2 drug tops Bristol Myers Sotyktu in head-to-head test (BioPharma Dive)
Jun-09-26 02:00AM	Inside Bristol Myers AI-powered procurement overhaul (CFO Dive)
Jun-08-26 09:07AM	Can MariTide Save Amgen Stock From Its Fading Blockbusters? (Trefis)
08:55AM	Is AbbVie Stock The Right Defensive Pick In This Volatile Market? (Trefis)
Jun-05-26 06:55PM	Is Amgen An Undervalued Stock Or Value Trap? (Trefis)
Jun-03-26 10:37AM	US lawmakers reveal policy to curb collaboration with Chinese biotech (Pharmaceutical Technology)
08:00AM	Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PDL1/VEGFA Bispecific Immunomodulator to Treat Kidney Cancer (Business Wire)
Jun-01-26 08:48AM	Bristol Myers Squibb Wins EU Green Light for Opdivo-Based Hodgkin Lymphoma Treatment (BMY) (InvestorsHub)
06:59AM	U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibbs Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) (Business Wire)
06:55AM	Bristol Myers Squibb Announces Opdivo (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma (Business Wire)
12:25AM	SMMT Stock Surges Overnight: Cancer Drug Survival Win Raises The Bar As PFE, BMY, MRK Chase Keytruda's Successor (Stocktwits)
May-29-26 08:14AM	Replimune takes third swing at cancer drug approval following productive FDA talks (BioPharma Dive)
08:04AM	How Bristol Is Building On Its $74 Billion Celgene Buyout With New 'Molecular Glue' (Investor's Business Daily)
08:00AM	Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma (Business Wire)
May-27-26 11:07AM	This Biotech Stock Is Stuck in the Red. Its Cancer Portfolio Is About to Change the Narrative. (Barrons.com)
11:06AM	Kardigan targets IPO to support cardiology pipeline progression (Pharmaceutical Technology)
08:07AM	Cardio drugmaker Kardigan plans to go public (BioPharma Dive)
May-26-26 12:42PM	Thinning revenues: inside the $14bn Eliquis patent cliff (Pharmaceutical Technology)
May-22-26 09:23PM	Fed Hawks Now Rule. Will Warsh Go Along with Them? (Barrons.com)
May-21-26 05:01PM	Bristol Myers Squibb to Unveil New Data at ASCO 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline (Business Wire)
06:18AM	BMS and Anthropic collaborate for Claude implementation (Hospital Management)
05:00AM	In Alzheimers, Bristol Myers sees big promise beyond amyloid (BioPharma Dive)
May-20-26 11:01AM	BioArctic AB (BRCTF) Q1 2026 Earnings Call Highlights: Strong Sales and Strategic Partnerships ... (GuruFocus.com)
09:52AM	Bristol-Myers Squibb is bringing Anthropic's Claude to 30,000 employees (Quartz)
07:48AM	Bristol Myers to deploy Anthropic's Claude AI model to speed up drug discovery (Reuters)
07:28AM	Bristol Myers deepens AI investment with Anthropic deal (BioPharma Dive)
06:59AM	Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global Operations (Business Wire)
May-19-26 09:33AM	Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout (Proactive)
May-18-26 07:04AM	Regeneron Shares Slide Premarket after Melanoma Drug Trial Disappoints (The Wall Street Journal)
03:55AM	Regeneron immunotherapy combo comes up short in melanoma trial (BioPharma Dive)
May-15-26 04:52AM	Former Ovid CEO Dr. Jeremy Levins rallying cry for biotech (Pharma Voice)
May-14-26 08:30AM	Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience (Business Wire)
May-13-26 08:57AM	Bristol-Myers Strikes $15.2 Billion China Drug Deal (GuruFocus.com)
May-12-26 11:10AM	BMS and Hengrui forge $15.2bn alliance for early-stage drugs (Pharmaceutical Technology)
09:48AM	Bristol Myers Squibb signs $15.2B licensing deal with Hengrui (Quartz)
08:30AM	Wall Street's Cardiac Bet: Where Diagnostics Meet the Money (PR Newswire)
04:18AM	Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion (BioPharma Dive)
02:35AM	Bristol-Myers Squibb and China's Hengrui Pharma Forge Tie-Up (The Wall Street Journal)
May-08-26 06:59AM	Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults (Business Wire)
May-06-26 06:48PM	Oncolytics Biotech Reports Data in Colorectal Cancer Study (IPO-Edge.com)

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

CEO & ChairmanDr. Christopher S. Boerner Ph.D.

Executive VP & CFOMr. David V. Elkins

Executive VP and Chief Digital & Technology OfficerMr. Greg Meyers

Executive VP & Chief Commercialization OfficerMr. Adam Lenkowsky

Executive VPMr. Cristian Massacesi M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Haller Julia A	Director	Jun 15 '26	Option Exercise	53.76	20,460	1,099,930	34,079	Jun 16 04:07 PM
Short Bartie Wendy	EVP, Corporate Affairs	Jun 03 '26	Option Exercise	0.00	8,040	0	15,957	Jun 05 04:10 PM
Lenkowsky Adam	EVP, Chief Commercial Officer	May 01 '26	Option Exercise	0.00	1,373	0	20,508	May 05 05:11 PM
Shanahan Karin	EVP, Chief Supply Chain & Ops	Apr 01 '26	Option Exercise	0.00	3,307	0	27,580	Apr 02 04:30 PM
Elkins David V	EVP, Chief Financial Officer	Apr 01 '26	Sale	61.67	30,000	1,850,016	159,248	Apr 02 04:29 PM
Elkins David V	Officer	Apr 01 '26	Proposed Sale	61.69	30,000	1,850,645		Apr 01 04:32 PM
Short Bartie Wendy	EVP, Corporate Affairs	Mar 10 '26	Option Exercise	0.00	5,883	0	10,952	Mar 12 04:22 PM
Shanahan Karin	EVP, Chief Supply Chain & Ops	Mar 10 '26	Option Exercise	0.00	25,501	0	39,120	Mar 12 04:21 PM
Plenge Robert M	EVP, Chief Research Officer	Mar 10 '26	Option Exercise	0.00	17,501	0	31,600	Mar 12 04:20 PM
Meyers Gregory Scott	EVP, Chief Digital & Tech Off.	Mar 10 '26	Option Exercise	0.00	25,892	0	44,330	Mar 12 04:19 PM
Lenkowsky Adam	EVP, Chief Commercial Officer	Mar 10 '26	Option Exercise	0.00	24,071	0	26,104	Mar 12 04:18 PM
Holzer Phil M	SVP and Controller	Mar 10 '26	Option Exercise	0.00	6,191	0	20,475	Mar 12 04:17 PM
Hoch Lynelle	President, Cell Therapy Org.	Mar 10 '26	Option Exercise	0.00	8,192	0	12,217	Mar 12 04:17 PM
Gallman Cari	EVP, General Counsel	Mar 10 '26	Option Exercise	0.00	6,980	0	17,039	Mar 12 04:16 PM
Poole Ahn Amanda	EVP, Chief People Officer	Mar 10 '26	Option Exercise	0.00	6,436	0	10,718	Mar 12 04:15 PM
BOERNER CHRISTOPHER S.	Chief Executive Officer	Mar 10 '26	Option Exercise	0.00	71,537	0	47,382	Mar 12 04:14 PM
Elkins David V	EVP, Chief Financial Officer	Mar 10 '26	Option Exercise	0.00	62,982	0	222,773	Mar 12 04:13 PM
Meyers Gregory Scott	EVP, Chief Digital & Tech Off.	Feb 01 '26	Option Exercise	0.00	2,543	0	22,261	Feb 03 04:40 PM
Hickey Benjamin	President, RayzeBio Org.	Feb 01 '26	Option Exercise	0.00	10,079	0	18,868	Feb 03 04:39 PM
BOERNER CHRISTOPHER S.	Chief Executive Officer	Nov 01 '25	Option Exercise	0.00	2,964	0	2,964	Nov 04 05:18 PM
Meyers Gregory Scott	EVP, Chief Digital & Tech Off.	Nov 01 '25	Option Exercise	0.00	6,281	0	22,383	Nov 04 05:15 PM
Shanahan Karin	EVP, Chief Supply Chain & Ops	Nov 01 '25	Option Exercise	0.00	6,281	0	20,078	Nov 04 05:13 PM
Gallman Cari	EVP, General Counsel	Oct 02 '25	Option Exercise	0.00	4,558	0	13,398	Oct 06 05:22 PM
Elkins David V	EVP, Chief Financial Officer	Sep 02 '25	Sale	47.33	56,000	2,650,480	167,379	Sep 03 06:46 PM
Short Bartie Wendy	EVP, Corporate Affairs	Sep 01 '25	Option Exercise	0.00	1,235	0	6,301	Sep 03 06:42 PM
Elkins David V	Officer	Sep 02 '25	Proposed Sale	47.30	56,000	2,648,800		Sep 02 11:16 AM
Short Bartie Wendy	EVP, Corporate Affairs	Aug 02 '25	Option Exercise	0.00	738	0	5,444	Aug 05 05:58 PM
Short Bartie Wendy	EVP, Corporate Affairs	Aug 02 '25	Sale	44.23	378	16,719	5,066	Aug 05 05:58 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BMY

Bristol-Myers Squibb Co

Upgrade your Finviz experience